Introduction {#sec0005}
============

Distinct cytogenetic subgroups of acute myeloid leukemia (AML) have been associated with age-specific frequencies and the incidence of unbalanced aberrations; in particular complex karyotypes increase sharply with age.[@bib0165] AML presenting the reciprocal translocation (8;16)(p11;p13) that generates the *MYST3-CREBBP* (former named as MOZ-CBP) fusion gene is mostly observed in adult patients.[@bib0170] The fusion of the *MYST3* and *CREBBP* genes occurs when both show histone acetyltransferase activities leading to the activation of several targets involved in transcriptional regulation and cell cycle control.[@bib0170], [@bib0175], [@bib0180] The evidence of AML with the *MYST3-CREBBP* fusion gene in children was reported by the International Berlin--Frankfurt--Munster (I-BFM) study group.[@bib0185] Sixty-two pediatric AML were identified in which karyotype records revealed t(8;16)(p11;p13) in the AML observed at an early age, monocyte differentiation \[French--American--British classification (FAB) AML-M5\] and presence of hemophagocytosis; all of which are associated with very poor outcomes.[@bib0185] Furthermore, the *MYST3-CREBBP* fusion gene associated with disseminated intravascular coagulation and high mortality rates was observed in a series of French AML patients.[@bib0190] These particular clinical, cytological, cytogenetic, and molecular characteristics of AML with *MYST3-CREBBP* led to the suggestion of a unique category in the World Health Organization (WHO) classification due to the poor prognosis.[@bib0195] Among the clinical spectrum conditions, hemophagocytic lymphohistiocytosis (HLH) should be included as differential diagnosis. However, HLH presents phagocyte activation caused by immune disorders that compromise T cell/natural killer cells and the normal monocyte-macrophage lineage.[@bib0200]

An accurate case identification requires the evaluation of morphological, cytogenetic and molecular features following correlation of obtained parameters, including serological tests. In this study, the availability of a unique series of early onset AML cases prompted us to search for AML-*MYST3-CREBBP* cases and to define relevant molecular cytogenetic characteristics.

Methods {#sec0010}
=======

Subjects {#sec0015}
--------

A series of 266 infant AML (i-AML) cases enrolled in the Brazilian Collaborative Study Group of Infant Acute Leukemia (BCSGIAL) from 2003 to 2012 is the reference cohort and subject for the present analysis.[@bib0205] The selection criteria were infants (≤24 months old) with a diagnosis of AML and the presence of hemophagocytosis by leukemic blasts ([Figure 1](#fig0005){ref-type="fig"}). Additionally, 48 i-AML cases without the hemophagocytic feature in the diagnostic samples were randomly selected to compare with i-AML cases with hemophagocytosis by blast cells.

Hemophagocytosis was defined as the presence of phagocytosis of red cells, lymphocytes and/or platelets only by blast cells. The morphological findings were discussed by physicians (RMB, TCCF, BF, IMQM) and cytologists (EPN, MSPO); clinical and laboratorial data were checked in each case for the consistency of inclusion criteria. Gender, age, white blood cell count (WBC), hemoglobin levels, platelet count, central nervous system (CNS) involvement, chloroma and cutaneous leukemia, FAB classification as well as the presence of hemophagocytosis by leukemic blasts were carefully reviewed. Exclusion criteria included secondary AML, down\'s syndrome, HLH and/or hemophagocytic syndrome associated with immune disorders and unexplained fever. Frozen samples from bone marrow (BM) aspirates, peripheral blood and smears of i-AML cases were selected for further cytogenetic and molecular studies according to the availability of good biological material.

All children were treated out of clinical trials, but following international AML protocols.

Characterization of leukemia cells {#sec0020}
----------------------------------

Leukemia classification of AML was based on criteria published by the WHO.[@bib0195] The diagnosis of AML-M7 was based on the presence of CD41/CD61 and CD42 markers on blast cells identified by immunophenotyping. Karyotypes of BM aspirates were tested before any chemotherapy treatment. Chromosomes were identified and analyzed as recommended by the International System of Human Cytogenetic Nomenclature (ISCN) 2005.[@bib0210]

Reverse transcription polymerase chain reaction {#sec0025}
-----------------------------------------------

Total RNA from BM mononuclear cells at the time of diagnosis was purified using the TRIzol reagent according to the manufacturer\'s instructions (Gibco/BRL, Life Technologies, CA, USA). Briefly, 2 μg of total RNA was reverse-transcribed using the First-Strand cDNA Synthesis Kit™ (Amersham Pharmacia Biotech Inc., NJ, USA). The integrity of cDNA was examined by amplifying a fragment of the *GAPDH* gene using previously described primers and cDNA was used as templates in subsequent polymerase chain reaction (PCR) assays. All cases were investigated for the presence of the *RUNX1-RUNX1T1*, *CBFβ-MYH11, BCR-ABL1, MLL-AFF1* and *MLL*-*MLLT3* fusion genes.[@bib0215], [@bib0220]

Detection of the *MYST3-CREBBP* and reverse *CREBBP-MYST3* fusion transcripts were conducted as described elsewhere.[@bib0225] Single PCR reactions to detect *MYST3*-*CREBBP* fusion transcripts type I (*MYST3* exon 16-*CREBBP* exon 3) and type II (*MYST3* exon 16-*CREBBP* exon 4), as well as the type I *CREBBP*-*MYST3* fusion transcript (*CREBBP* exon 2-*MYST3* exon 17) were performed using the primers listed in [Table 1](#tbl0005){ref-type="table"}. A semi-nested reaction, adapted from Schmidt et al., was required to detect type I transcripts.[@bib0225] Samples from confirmed AML cases with *MYST3-CREBBP* were added as positive controls for type I transcripts. PCR products for *MYST3*-*CREBBP* transcripts (type I-II) were separated by electrophoresis in 1.5% agarose gel and subsequently purified using NucleoSpin Gel and PCR Clean-up kits (Macherey-Nagel, VWR International, Oslo, Norway). Amplicons were mixed with the Big Dye terminator v3.1 Kit (Applied Biosystems) and forward or reverse primers and sequenced in an ABI 3130xl Genetic Analyzer (Applied Biosystems).

The identification of somatic mutations in *KRAS*, *FLT3* and c-*KIT* genes were performed by direct sequencing.[@bib0230], [@bib0235], [@bib0240]

Fluorescence in situ hybridization {#sec0030}
----------------------------------

Fluorescence in situ hybridization (FISH) for the *MLL* rearrangements was performed at the time of diagnosis with fresh biological material using a commercial LSI MLL Dual Color, Break Apart Rearrangement probe (Cytocell Ltd., Cambridge, UK) according to the manufacturer\'s instructions. The *MYST3-CREBBP* FISH was performed in interphase nuclei prepared from frozen viable cells of available cases using bacteria-derived artificial chromosome (BAC). These clones were retrieved from the human genome high resolution BAC re-arrayed clone set available in a web format ([http://bacpac.chori.org](http://bacpac.chori.org/){#intr0005}) and selected according to physical and genetic mapping data reported on Ensembl Browser website ([http://www.ensembl.org](http://www.ensembl.org/){#intr0010}). DNA was extracted and probes were labeled and hybridized by Blue Genome (Cambridge, UK), with Spectrum Orange or Spectrum Green and validated as a FISH probe set on normal controls. The clones used were RP11-231D20 (chr8:42184655-42188062) and RP11-108L9 (chr8:41832025-41864392) flanking the *MYST3* gene (orange) and RP11-387O21 (chr16:3918191-4104380) and RP11-461A8 (chr16:3663996-3693579) flanking the *CREBBP* gene (green). Procedures were performed according to the manufacturer\'s instructions. The first step was FISH mapping of clones on normal cells from healthy blood donors in order to confirm their chromosomal location. Cut-off values were calculated as 6 ± 3% of fusion gene signals in 100--300 interphase nuclei.

Ethical considerations {#sec0035}
----------------------

Treatment was approved by local laws and regulations as well as by the Institutional Review Boards of each participating center. Medical informed consent was obtained in accordance with the Declaration of Helsinki. This study was approved by the Research Ethics Committee at the Instituto Nacional de Câncer in Rio de Janeiro, Brazil (CEP/CAEE: 186.688).

Results {#sec0040}
=======

The clinical-demographic characteristics of the eleven cases that fulfilled the selection criteria are shown in [Table 2](#tbl0010){ref-type="table"}. All patients presented hepatosplenomegaly and three were reported to have chloroma and one CNS disease. The majority of the patients were male (72.7%) with a median age of 12 months (range: 0--23 months). The WBC count varied from 5.7 to 111.1 × 10^9^/L with a median of 35.9 × 10^9^/L; six cases were diagnosed as myelomonocytic leukemia (M4/M5), three cases as AML-M7 and two as AML-M2. Serological tests for viral infections (Epstein--Barr virus, parvovirus B19 and human immunodeficiency virus) and coagulation examinations were within normal ranges. No infections triggering HLH were found in any of the eleven cases.

Using the selected BAC clones of the *MYST3*-*CREBBP* fusion gene, three types of hybridization patterns were observed ([Figure 2](#fig0010){ref-type="fig"}). The first, separated signals of the probe combinations RP11-231D20/RP11-108L9 and RP11-387O21/RP11-461A8 on chromosomes 8 and 16 respectively, were observed as four different signals: two red and two green distinct signals consistent with normal chromosomes ([Figure 2](#fig0010){ref-type="fig"}A). Second, a single fusion pattern was observed (one fusion, one red and one green) considered as a random co-localized signal ([Figure 2](#fig0010){ref-type="fig"}B). Lastly, a dual fusion signal was found in 15--37% of the interphase nuclei analyzed which was consistent with a breakpoint in *MYST3* and *CREBBP* ([Figure 2](#fig0010){ref-type="fig"}C).

The RT-PCR technique was performed in 55 samples; seven samples were from i-AML with hemophagocytosis ([Table 3](#tbl0015){ref-type="table"}) and 48 samples from i-AML without hemophagocytosis. The RT-PCR pattern was different to expected (∼1000 bp) in one case, with a ∼900 bp product observed (\#1). In five cases (\#3, \#5, \#6, \#7 and \#10), RT-PCR was negative for type I and II transcripts. Despite accurate mapping of the translocation breakpoints, attempts to amplify the transcripts, as well as the *CREBPP-MYST3* were not successful. In four cases (\#2, \#4, \#8 and \#9), RT-PCR was not performed due to lack of suitable biological material. Discrepancies were observed in three cases (\#3, \#5 and \#6) in which dual fusion signals were found in 15--18% and 34% of the interphase nuclei analyzed and RT-PCR results were negative. In all the i-AML cases without hemophagocytosis, the RT-PCR results were negative ([Figure 3](#fig0015){ref-type="fig"}).

As shown in [Table 3](#tbl0015){ref-type="table"}, the diagnosis of the *MYST3-CREBBP* fusion gene was based on the FISH results only or combined with the RT-PCR results. Five cases were diagnosed as AML-*MYST3-CREBBP* and clinical laboratorial features are summarized: they presented hepatosplenomegaly, skin lesions and/or localized chloroma; hematological tests revealed FAB AML-M2, M4, M5, or M7; the presence of hemophagocytosis by blast cells varied from 5 to 25%. The immunophenotyping profile showed cells positive for the CD34, CD33/CD13/CD14/CD11b/CD14/CD15, CD64, CD56 antigens; in three patients, the blast cells were positive for CD61/CD41a/CD42b/CD56; karyotyping was successful in four cases; one case (\#1) revealed a 46, XX, der (16), t(16;?) (p13;?) without identified partners on the short arm of chromosome 16.

None of the eleven AML cases presented with the R*UNX1-RUNX1T1, CBFb-MYH11, BCR-ABL1, MLL-AFF1, MLL-MLLT1, KRAS, FLT3* or *c-KIT* mutations.

The patients received AML treatment according to the BFM AML-2004 protocol and only one out of five patients with the AML *MYST3-CREBBP* fusion gene is still alive.

Discussion {#sec0045}
==========

Chromosomal abnormalities in childhood AML are frequent; the *MYST3-CREBBP* rearrangement, however, is not.[@bib0165], [@bib0245] Here, we report for the first time the presence of *MYST3-CREBBP* rearrangement in five out of eleven (36.4%) AML cases with hemophagocytosis found in a Brazilian i-AML cohort. The morphological observation of hemophagocytosis was an important variable for the selection criteria to investigate the *MYST3-CREBBP* fusion gene. Clinically, these cases appear to have distinct disease manifestations with skin nodules, CNS involvement and chloroma.[@bib0165], [@bib0185], [@bib0250] As pointed out by Hatano et al., other chromosomal abnormalities in AML, such as t(16;21)(p11;q22), karyotypes involving the 8p11 breakpoint, t(8;19)(p11;q32), complex rearrangements and other chromosomal translocations are associated with the presence of hemophagocytosis by blast cells.[@bib0255] This supports our data showing an absence of the *MYST3-CREBBP* fusion gene in four cases in this study. According to the literature, in the majority of patients described with myelomonocytic morphology, the presence of CD56 cellular expression predicts an association with hemophagocytosis and involvement of the leukemia cutis.[@bib0165], [@bib0185], [@bib0255], [@bib0260], [@bib0265], [@bib0270]

The technique used to identify this chromosomal alteration was FISH because conventional karyotyping was not always available. Failure to obtain mitosis was a pitfall. Multicolor karyotyping technologies such as multicolor-FISH would certainly elucidate such subtle chromosomal rearrangements if mitosis were successfully obtained. Based on hematological signs, we chose to carry out the FISH method followed by RT-PCR as a laboratorial strategy to search for the *MYST3-CREBBP* fusion gene. The FISH analysis showed a fusion signal above the cutoff value for the specific *MYST3* and *CREBBP* probes on interphase nuclei, suggesting the presence of a *MYST3-CREBBP* fusion chimera in five cases. This finding indicates a possible generation of *MYST3-CREBBP*, since both chromosome regions represented by the clones that contain the *MYST3* and *CREBBP* genes appeared co-localized. In one case, RT-PCR for the type I fusion transcript followed by direct sequencing showed a ∼900 pb transcript probably related to an unspecific amplification. In the other four cases, no amplicon was observed. Type I (*MYST3* exon 16-*CREBBP* exon 3) is the most common form in adults with *MYST3-CREBBP* AML.[@bib0240], [@bib0275] Low expression or instability of the chimeric transcripts[@bib0280] and RNA degradation might explain the absence of amplification by RT-PCR.

Recently, Panagopoulos et al. described an AML with hemophagocytosis and with two translocations with breakpoints that suggest other candidate genes different to *MYST3* and *CREBBP*.[@bib0285] They studied the patients' leukemic cells not only by karyotyping, FISH and RT-PCR, but also using the modern RNA-seq technique and programs that are specific for fusion genes. Interestingly, the techniques initially failed to detect the biologically important *MYST3-CREBBP* fusion, although it was manually retrievable from the raw sequencing data, suggesting that additional information about clinical, morphological, and molecular cytogenetic features should be taken into account when searching for newly described crucial fusion genes in typical hematologic malignancies.[@bib0285]

One important point should be discussed is related to AML-*MYST3-CREBBP* and the differential diagnosis of a hemaphagocytic syndrome such as HLH, which is a severe hyperinflammatory condition with clinical symptoms that include fever, cytopenias, hepatosplenomegaly, and hemophagocytosis.[@bib0290] However, this hemophagocytosis in BM is morphological in benign macrophages. HLH, when occurring in young children, is associated with inherited genetic defects and diagnostic criteria combine both biological features, including natural killer cell activity and high-soluble interleukin-2-receptor levels.[@bib0295]

AML cases younger than two years old with hemophagocytosis should be investigated for the presence of the *MYST3-CREBBP* and other chromosomal alterations. In the I-BFM AML study group, more than 50% of the *MYST3-CREBBP* cases were found in infants and the frequency of congenital cases was significantly higher.[@bib0185] One of our cases described herein was congenital leukemia. Some authors consider that congenital AML-*MYST3-CREBBP* may be a self-limiting disease reaching spontaneous remission. A 'watch-and-wait' policy should be considered in congenital patients with mild clinical symptoms provided that close long-term monitoring is used.[@bib0185], [@bib0300], [@bib0305], [@bib0310] However, cases from our cohort suffered from aggressive disease with dismal outcomes. Interestingly, the genomic landscape of childhood AML-*MYST3-CREBBP* has a specific signature clustered close to AML with *MLL* rearrangements.[@bib0185], [@bib0315], [@bib0320] The similarity consists in the characteristic pattern of up-regulation of *HOXA9, HOXA10*, and cofactor *MEIS1* and down-regulation of other *homeobox* family genes.[@bib0320] The high frequency of AML-*MYST3-CREBBP* in infants (≤24 months) and congenital cases support the hypothesis that leukemia occurs during the *in utero* life and as in the *MLL* rearrangements model they should be explored for a better understanding of AML leukemogenesis.
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![Morphology of AML-M4 with hemophagocytosis by blast cells. Bone marrow aspiration stained by May--Grunwald--Giemsa shows myeloblast and monoblast cells with phagocytosis of red cells and lymphocytes.](gr1){#fig0005}

![FISH pattern of *MYST3-CREBBP* probes. Three types of hybridization patterns were observed: two red and two green signals (A); a single fusion pattern, with one red and one green signal remaining (B); and a dual fusion signal (C).](gr2){#fig0010}

![Agarose gel images of RT-PCR for *MYST3-CREBBP* fusion genes. Gel A, shows positive reactions for the *MYST3-CREBBP* fusion gene. Samples 2 (A) and 19 (B) are the positive controls in each reaction. Sample 1 (A and B) is the negative control (H~2~O only). Samples 3 and 5 (A) are from patients \#1 and \#11. In gel B, all samples are negative for the *MYST3-CREBBP* fusion gene; M: standard marker (100 base pairs)](gr3){#fig0015}

###### 

Sequences of the primers used for reverse transcription polymerase chain reaction.

Table 1

  Designation   Sequence (from 5′ to 3′)   Position
  ------------- -------------------------- -------------
  MOZ3558F      GAGGCCAATGCCAAGATTAGAAC    MOZ exon 16
  CBP1201R      GTTGCAATTGCTTGTGTGGGTAC    CBP exon 5
  MOZ3536F      CCTTTTGAAGATTCTGACTCCG     MOZ exon 16
  CBP404R       CCTCGTAGAAGCTCCGACAGTT     CBP exon 3
  CBP96F        CGCTCGCTCCTCTCCCTCGCAG     CBP exon 2
  MOZ3953R      TGGAAACGATGGGCTCAATGACGC   MOZ exon 17
  CBP174F       GGGCTGTTTTCGCGAGCAGGTG     CBP exon 2
  MOZ3844R      GGCTCTTGCCTTTGGGCCATCC     MOZ exon 17

###### 

Demographic and clinical characteristics of selected i-AML cases.

Table 2

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Case   Age (Mo.)   Gender   Clinical features     Hb (g/dL)   WBC (×10^9^/L)   Plat count (×10^9^/L)   Hemoph\*   FAB   Conclusion       Outcome
  ------ ----------- -------- --------------------- ----------- ---------------- ----------------------- ---------- ----- ---------------- ----------
  1      12          F        Hepatosplenomegaly    5.68        111.1            40.0                    \+         M4    AML-M4\          Deceased
                                                                                                                          *MYST3-CREBPP*   

  2      11          M        Hepatosplenomegaly    4.0         25.4             26.0                    \+         M5    AML-M5           Alive

  3      \<1         F        Hepatosplenomegaly\   10.7        8.6              29.0                    \+         M4    AML-M4\          Deceased
                              Chloroma                                                                                    *MYST3-CREBPP*   

  4      12          M        Hepatosplenomegaly    4.2         36.8             35.0                    \+         M2    AML-M2\          Alive
                                                                                                                          *MYST3-CREBPP*   

  5      18          M        Hepatosplenomegaly\   7.0         5.7              3.0                     +/−        M5    AML-M5\          Deceased
                              Chloroma                                                                                    *MYST3-CREBPP*   

  6      23          M        Hepatosplenomegaly    4.6         42.4             57.0                    +/−        M7    AML-M7\          Alive
                                                                                                                          *MYST3-CREBPP*   

  7      10          M        Hepatosplenomegaly\   10.7        35.0             229.0                   \+         M2    AML-M2           Alive
                              Chloroma                                                                                                     

  8      13          M        Hepatosplenomegaly    6.2         61.6             45.0                    \+         M5    AML-M5           Alive

  9      22          M        Hepatosplenomegaly\   5.0         25.9             31.0                    \+         M7    AML-M7           Deceased
                              CNS^POS^                                                                                                     

  10     12          M        Hepatosplenomegaly    5.5         45.0             100.0                   \+         M5    AML-M5           Deceased

  11     11          F        Hepatosplenomegaly    7.0         8.5              20.0                    \+         M7    AML-M7           Deceased
  ---------------------------------------------------------------------------------------------------------------------------------------------------

F: female; M: male; (\*), Hemoph: hemophagocytosis (range: 5--27% blasts with phagocytosis); Hb: hemoglobin concentration; i-AML: infant acute myeloid leukemia; Mo: months; FAB: French--American--British classification; NOS: not otherwise specified; Plat: platelet count; WBC: white blood cell count.

###### 

Immunophenotyping, cytogenetic, fluorescence in situ hybridization (FISH) and reverse transcription polymerase chain reaction (RT-PCR) of infant acute myeloid leukemia cases with hemophagocytosis.

Table 3

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case   Immunophenotype                           Cytogenetics                         FISH (%)   *RT*-*PCR*[a](#tblfn0005){ref-type="table-fn"}   Conclusion
  ------ ----------------------------------------- ------------------------------------ ---------- ------------------------------------------------ --------------------------------------------------
  1\.    CD33/CD13/CD14/CD11b^pos^                 46, XX, der(16) t(16;?)(p13;?)^35^   37         Type-I                                           *MYST-CREBPP*

  2\.    CD34/CD33/CD13/CD4^pos^/CD14^neg^.        46, XY^10^                           9          NT                                               --

  3\.    CD33CD33/CD13/CD14/CD11b^neg^             NT                                   18         NEG                                              *MYST-CREBPP*

  4\.    CD33/CD13/CD7/CD117/CD56^pos^             NT                                   10         NT                                               *MYST-CREBPP*

  5\.    CD34/CD33/CD13/CD14^pos^/CD15/CD16^pos^   NT                                   34         NEG                                              *MYST-CREBPP*

  6\.    CD34/CD33/CD13^pos^\                      NT                                   15         NEG                                              *MYST-CREBPP*
         CD61/CD41a/CD42b/CD56^pos^                                                                                                                 

  7\.    CD34/CD33/CD13/CD117^pos^                 NT                                   6          NEG                                              --

  8\.    CD34/CD33/CD13/CD117/CD14^neg^            45, XY, t(8;8)(q21;1p25) ^10^        8          NT                                               --

  9\.    CD34/CD33/CD13, CD56 ^pos^, CD61^Neg^     46, XY, 16H+^12^                     6          NT                                               --

  10\.   NT                                        NT                                   9          NEG                                              --

  11\.   CD42/CD61                                 NT                                   9          Type-I                                           Undetermined[a](#tblfn0005){ref-type="table-fn"}
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

--: Considered negative; NT: not tested; NEG: Negative.

Undetermined because the FISH cut-off values were calculated as 6 ± 3% of fusion gene signals, and discordant result with the RT-PCR, the type-I fragment length was not as expected.
